AR020323A1 - Preparaciones farmaceuticas estabilizadas que contienen derivados de acido 4-amino-3-substituido butanoico y proceso para prepararlos - Google Patents
Preparaciones farmaceuticas estabilizadas que contienen derivados de acido 4-amino-3-substituido butanoico y proceso para prepararlosInfo
- Publication number
- AR020323A1 AR020323A1 ARP990102313A ARP990102313A AR020323A1 AR 020323 A1 AR020323 A1 AR 020323A1 AR P990102313 A ARP990102313 A AR P990102313A AR P990102313 A ARP990102313 A AR P990102313A AR 020323 A1 AR020323 A1 AR 020323A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- amino
- substituted
- alkyl
- mono
- Prior art date
Links
- -1 4-AMINO-3-SUBSTITUTED BUTANOIC ACID Chemical class 0.000 title abstract 4
- 239000000825 pharmaceutical preparation Substances 0.000 title abstract 3
- 238000000034 method Methods 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 5
- 125000003545 alkoxy group Chemical group 0.000 abstract 4
- 125000004414 alkyl thio group Chemical group 0.000 abstract 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 4
- 125000005843 halogen group Chemical group 0.000 abstract 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 4
- 125000003277 amino group Chemical group 0.000 abstract 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 3
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 2
- 125000006564 (C4-C8) cycloalkyl group Chemical group 0.000 abstract 2
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 abstract 2
- 125000000081 (C5-C8) cycloalkenyl group Chemical group 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 150000001370 alpha-amino acid derivatives Chemical class 0.000 abstract 1
- 235000008206 alpha-amino acids Nutrition 0.000 abstract 1
- 230000000903 blocking effect Effects 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 229960002870 gabapentin Drugs 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 125000004043 oxo group Chemical group O=* 0.000 abstract 1
- 229960001233 pregabalin Drugs 0.000 abstract 1
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polymerisation Methods In General (AREA)
Abstract
Preparaciones farmacéuticas que incluyen derivados del ácido 4-amino-3-sustituido-butanoico, que son efectivos para bloquear los grupos aminoy carboxilo, y un aminoácido alfa para obtener una estabilidad superior en almacenamiento, no solo en laform a de solucion sino también en estadosolido. Dichos derivados comprenden preferentemente gabapentina, pregabalina, bacolofeno y otros. Una preparacion farmacéutica estabilizada, con underivado del ácido 4-amino-3-sustituido-butanoico de formula(1), d onde R1 es un átomo de hidrogeno, un grupo hidroxilo, un grupo metilo o un grupo etilo;R2 es un grupo monovalente seleccionado a partir de: un grupo alquilo recto o ramificado C3-8; un grupo alquileno recto o ramificado C3-8; ungrupo alquilorecto o ramificado C3-8 que es mono- o di-sustituido con un átomo de halogeno, un grupo trifluorometilo, un grupo hidroxilo, un grupoalcoxi, un grupo alquiltio, un grupo amino, un grupo nitro, un grupo oxo, un grupo carboxilo o un grupo carboalcoxi;un grupo cicloalquilo C3-8; ungrupo cicloalquilo C3-8 que es mono-, di- o tri-sustituido con un átomo de halogeno, un grupo trifluorometilo, un grupo hidroxilo, un grupo alquilo, un grupoalcoxi, un grupo alquiltio, un grupo amino, un grupo nitro, ungrupo ox o, un grupo carboxil o un grupo carboalcoxi; un grupo de anillo condensado formadopor orto-fusion de un anillo fenilo con un grupo cicloalquilo C4-8; un grupo de anillo condensado formado por orto-fusion de un anillo fenilocon un grupocicloalquilo C 4-8 donde dicho anillo fenilo es mono-, di- o tri-sustituido con un átomo de halogeno, un grupo trifluorometilo, un grupohidroxilo, un grupo alquilo, un grupo alcoxi, un grupo alquiltio, un grupo amino, un grupo nitro, un grupocarboxilo o un grupo c arboalcoxi; un grupo de anillocondensado formado por orto-fusion de un anillo fenilo con un grupo cicloalquenilo C5-8 o un grupo cicloalcanodienilo C5-8 donde dicho anillo es mono-,di-, o tri-sustituido con un átomo dehalogeno, un grupo trifluoromet ilo, un grupo hidroxilo, un grupo alquilo, un grupo alcoxi, un grupo alquiltio,
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP13311398 | 1998-05-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR020323A1 true AR020323A1 (es) | 2002-05-08 |
Family
ID=15097118
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP990102313A AR020323A1 (es) | 1998-05-15 | 1999-05-14 | Preparaciones farmaceuticas estabilizadas que contienen derivados de acido 4-amino-3-substituido butanoico y proceso para prepararlos |
Country Status (37)
Country | Link |
---|---|
US (1) | US7309719B1 (es) |
EP (1) | EP1077692B1 (es) |
JP (1) | JP4612923B2 (es) |
KR (1) | KR100602047B1 (es) |
CN (1) | CN1303991C (es) |
AR (1) | AR020323A1 (es) |
AT (1) | ATE271864T1 (es) |
AU (1) | AU768277B2 (es) |
BR (1) | BR9910508B1 (es) |
CA (1) | CA2327285C (es) |
CO (1) | CO5021224A1 (es) |
CR (1) | CR6026A (es) |
CU (1) | CU23253B7 (es) |
DE (1) | DE69918977T2 (es) |
DK (1) | DK1077692T3 (es) |
EG (1) | EG26803A (es) |
ES (1) | ES2221385T3 (es) |
GT (1) | GT199900069A (es) |
HK (1) | HK1036586A1 (es) |
HN (1) | HN1999000072A (es) |
HU (1) | HU228771B1 (es) |
ID (1) | ID27724A (es) |
IL (2) | IL139298A0 (es) |
IS (1) | IS2233B (es) |
MY (1) | MY157878A (es) |
NO (1) | NO328959B1 (es) |
NZ (1) | NZ508015A (es) |
PA (1) | PA8472801A1 (es) |
PE (1) | PE20000556A1 (es) |
PL (1) | PL204921B1 (es) |
PT (1) | PT1077692E (es) |
SI (1) | SI1077692T1 (es) |
SV (1) | SV1999000064A (es) |
TW (1) | TWI243054B (es) |
UY (1) | UY25512A1 (es) |
WO (1) | WO1999059573A1 (es) |
ZA (1) | ZA200006484B (es) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1094757C (zh) | 1996-07-24 | 2002-11-27 | 沃尼尔·朗伯公司 | 用于治疗疼痛的异丁基γ-氨基丁酸及其衍生物 |
EP1384473A1 (en) * | 2000-06-16 | 2004-01-28 | Teva Pharmaceutical Industries Ltd. | Stable gabapentin containing more than 20 ppm of chlorine ion |
EP1430893A1 (en) * | 2000-06-16 | 2004-06-23 | Teva Pharmaceutical Industries Ltd. | Stable gabapentin containing more than 20 ppm of chloride ion |
TR200302296T4 (tr) * | 2000-06-16 | 2004-02-23 | Teva Pharmaceutical Industries Ltd. | 20 ppm klor iyonundan daha çok ihtiva eden kararlı gabapentin |
SK302003A3 (en) * | 2000-06-16 | 2003-07-01 | Teva Pharma | Stable gabapentin having pH within a controlled range |
US7056951B2 (en) * | 2000-09-26 | 2006-06-06 | Mutual Pharmaceutical Co., Inc. | Stable solid dosage forms of amino acids and processes for producing same |
SI1395242T1 (en) | 2001-05-25 | 2006-10-31 | Warner Lambert Co | Liquid pharmaceutical composition |
RU2340331C2 (ru) * | 2004-02-04 | 2008-12-10 | Алембик Лимитед | Форма пролонгированного высвобождения венлафаксина гидрохлорида |
CA2565095A1 (en) * | 2004-05-17 | 2005-12-08 | William S. Brusilow | Decreasing brain neuronal glutamate levels using alpha-keto branched chain amino acids |
NL2000281C2 (nl) | 2005-11-02 | 2007-08-07 | Pfizer Prod Inc | Vaste farmaceutische samenstellingen die pregabaline bevatten. |
WO2007107835A2 (en) * | 2006-03-17 | 2007-09-27 | Aurobindo Pharma Limited | Stable liquid formulations of antiepileptic agents |
DE102007019071A1 (de) | 2007-04-23 | 2008-10-30 | Ratiopharm Gmbh | Stabilisierte pharmazeutische Zusammensetzung enthaltend Pregabalin |
FR2918567B1 (fr) * | 2007-07-11 | 2012-08-03 | Pf Medicament | Composition pharmaceutique stable d'un sel hydrosoluble de vinorelbine. |
EP2116618A1 (en) | 2008-05-09 | 2009-11-11 | Agency for Science, Technology And Research | Diagnosis and treatment of Kawasaki disease |
AU2010250766B2 (en) | 2009-05-19 | 2015-04-09 | Neuroderm Ltd | Compositions for continuous administration of dopa decarboxylase inhibitors |
HU230031B1 (hu) | 2010-03-01 | 2015-05-28 | Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság | Pregabalint és izomaltot tartalmazó stabilizált gyógyszerkészítmény |
TR201005241A1 (tr) | 2010-05-25 | 2012-01-23 | Sanovel �La� San. Ve T�C. A.�. | Kontrollü salım sağlayan pregabalin solüsyon formülasyonu. |
EP2389934A1 (en) | 2010-05-25 | 2011-11-30 | Sanovel Ilac Sanayi ve Ticaret A.S. | Controlled-Release Tablet Formulations of Pregabalin |
EP2389933A1 (en) | 2010-05-25 | 2011-11-30 | Sanovel Ilac Sanayi ve Ticaret A.S. | Controlled-Release Pregabalin Compositions |
PT2640358T (pt) | 2010-11-15 | 2018-02-23 | Neuroderm Ltd | Administração contínua de l-dopa, inibidores de dopa descarboxilase, inibidores de catecol-o-metil transferase e composições para os mesmos |
CN104349768B (zh) | 2012-06-05 | 2017-11-07 | 纽罗德姆有限公司 | 包含阿朴***和有机酸的组合物及其用途 |
CN103494796B (zh) * | 2013-09-30 | 2016-01-20 | 浙江华义医药有限公司 | 普瑞巴林稳定的药物组合物及其制备方法 |
WO2015114509A1 (en) | 2014-01-28 | 2015-08-06 | Ranbaxy Laboratories Limited | Stabilized gastroretentive tablets of pregabalin |
HRP20231716T1 (hr) | 2014-03-13 | 2024-03-15 | Neuroderm Ltd. | Pripravci inhibitora dopa dekarboksilaze |
US10258585B2 (en) | 2014-03-13 | 2019-04-16 | Neuroderm, Ltd. | DOPA decarboxylase inhibitor compositions |
WO2015144825A1 (en) * | 2014-03-27 | 2015-10-01 | Sanovel Ilac Sanayi Ve Ticaret A.S. | Oral liquid pharmaceutical solution of gabapentin |
EP2929878A1 (en) * | 2014-04-09 | 2015-10-14 | Arven Ilac Sanayi ve Ticaret A.S. | Extended release formulations of gabapentin |
JP2018520112A (ja) | 2015-05-26 | 2018-07-26 | オディディ,イサ | 制御持続放出プレガバリン |
JP6919119B2 (ja) * | 2017-01-23 | 2021-08-18 | 日新製薬株式会社 | 3位が置換されたγ−アミノ酪酸誘導体を含有する圧縮固形医薬組成物。 |
WO2020071546A1 (ja) | 2018-10-04 | 2020-04-09 | 株式会社 メドレックス | 非水系溶媒により安定化された製剤 |
US11654124B2 (en) | 2019-07-29 | 2023-05-23 | Amneal Pharmaceuticals Llc | Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives |
US10792262B1 (en) * | 2019-07-29 | 2020-10-06 | Saol International Limited | Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives |
US20220296548A1 (en) | 2019-10-25 | 2022-09-22 | Kyoto University | Preventative or therapeutic agent for tauopathy |
US11331293B1 (en) | 2020-11-17 | 2022-05-17 | Neuroderm, Ltd. | Method for treatment of Parkinson's disease |
US11213502B1 (en) | 2020-11-17 | 2022-01-04 | Neuroderm, Ltd. | Method for treatment of parkinson's disease |
US11844754B2 (en) | 2020-11-17 | 2023-12-19 | Neuroderm, Ltd. | Methods for treatment of Parkinson's disease |
CN112843015A (zh) * | 2021-04-08 | 2021-05-28 | 海南鑫开源医药科技有限公司 | 一种加巴喷丁胶囊制剂及其制备方法 |
WO2023055457A1 (en) | 2021-09-29 | 2023-04-06 | Amneal Pharmaceuticals Llc | Baclofen-containing granule formulations and reduced patient exposure to metabolite variations |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4087544A (en) | 1974-12-21 | 1978-05-02 | Warner-Lambert Company | Treatment of cranial dysfunctions using novel cyclic amino acids |
DE2460891C2 (de) | 1974-12-21 | 1982-09-23 | Gödecke AG, 1000 Berlin | 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel |
US4126684A (en) * | 1976-02-11 | 1978-11-21 | Ciba-Geigy Corporation | 4-amino-3-p-halophenylbutyric acids and their derivatives used in the control of narcotic abuse |
US4255448A (en) * | 1979-09-10 | 1981-03-10 | Wisconsin Alumni Research Foundation | Method for reducing epileptiform activity |
GB8311804D0 (en) * | 1983-04-29 | 1983-06-02 | Merrell Toraude & Co | Treatment of seizure disorders and pharmaceutical compositions |
US4595697A (en) * | 1984-03-28 | 1986-06-17 | Merrell Dow Pharmaceuticals Inc. | Treatment of seizure disorders and pharmaceutical compositions useful therein |
CA1249968A (en) * | 1984-04-05 | 1989-02-14 | Kazuo Kigasawa | Ointment base |
JPS63253022A (ja) | 1987-04-08 | 1988-10-20 | Nitto Electric Ind Co Ltd | バクロフエン外用製剤 |
PH26730A (en) | 1988-12-30 | 1992-09-28 | Ciba Geigy Ag | Coated adhesive tablets |
DE3928183A1 (de) * | 1989-08-25 | 1991-02-28 | Goedecke Ag | Lactamfreie cyclische aminosaeuren |
US5006560A (en) * | 1989-12-20 | 1991-04-09 | Schering Corporation | Use of GABA-B selective agonists as anti-tussive agents |
US5084479A (en) * | 1990-01-02 | 1992-01-28 | Warner-Lambert Company | Novel methods for treating neurodegenerative diseases |
EP0458751A1 (en) * | 1990-05-25 | 1991-11-27 | Warner-Lambert Company | Delivery system for cyclic amino acids with improved taste, texture and compressibility |
US5025035A (en) | 1990-10-12 | 1991-06-18 | Warner-Lambert Company | Method of treating depression |
GB9023585D0 (en) * | 1990-10-30 | 1990-12-12 | Beecham Group Plc | Novel compounds |
HUT59656A (en) * | 1990-11-15 | 1992-06-29 | Puetter Medice Chem Pharm | Process for producing s/+/-phenyl-alkanoic acids and alpha-amino-acids containing complexes and pharmaceutical compositions containing them as active components |
US6197819B1 (en) * | 1990-11-27 | 2001-03-06 | Northwestern University | Gamma amino butyric acid analogs and optical isomers |
JPH0597703A (ja) * | 1991-10-04 | 1993-04-20 | Yamanouchi Pharmaceut Co Ltd | 改変型組織プラスミノーゲン活性化因子含有組成物 |
HU222339B1 (hu) * | 1992-05-20 | 2003-06-28 | Northwestern University | S-(+)-4-amino-3-(2-metil-propil)-butánsav, és gyógyászati szempontból elfogadható sói, ezeket tartalmazó gyógyászati készítmények, valamint az (S)-(+)-4-amino-3-(2-metil-propil)-butánsav előállítása |
US5629008A (en) * | 1992-06-02 | 1997-05-13 | C.R. Bard, Inc. | Method and device for long-term delivery of drugs |
US5792451A (en) * | 1994-03-02 | 1998-08-11 | Emisphere Technologies, Inc. | Oral drug delivery compositions and methods |
US5248678A (en) * | 1992-06-30 | 1993-09-28 | Fractal Laboratories, Inc. | Methods for increasing arousal and alertness and for the amelioration of comatose states |
US5260337A (en) * | 1992-07-29 | 1993-11-09 | Merck & Co., Inc. | Ibuprofen-muscle relaxant combinations |
JP3467794B2 (ja) * | 1993-03-09 | 2003-11-17 | 日本油脂株式会社 | 学習能向上剤 |
ZA953078B (en) * | 1994-04-28 | 1996-01-05 | Alza Corp | Effective therapy for epilepsies |
JPH0867636A (ja) * | 1994-08-30 | 1996-03-12 | Yamanouchi Pharmaceut Co Ltd | 播種性血管内凝固症候群(dic)の予防治療薬 |
GB9420784D0 (en) * | 1994-10-14 | 1994-11-30 | Glaxo Group Ltd | Medicaments |
US5641512A (en) * | 1995-03-29 | 1997-06-24 | The Procter & Gamble Company | Soft gelatin capsule compositions |
US5510381A (en) | 1995-05-15 | 1996-04-23 | Warner-Lambert Company | Method of treatment of mania and bipolar disorder |
JPH1017476A (ja) * | 1996-06-28 | 1998-01-20 | Nippon Seiyaku Kk | 敗血症用非経口製剤及びそれによる予防及び治療方法 |
AU735389B2 (en) * | 1996-07-22 | 2001-07-05 | Cognetix, Inc. | Use of conantokins |
CN1094757C (zh) * | 1996-07-24 | 2002-11-27 | 沃尼尔·朗伯公司 | 用于治疗疼痛的异丁基γ-氨基丁酸及其衍生物 |
US5780431A (en) * | 1996-09-20 | 1998-07-14 | Neurobiological Technologies, Inc. | Pharmaceutical formulations of corticotropin releasing factor having improved stability in liquid form |
US6028102A (en) * | 1998-02-24 | 2000-02-22 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Anticonvulsant drugs and pharmaceutical compositions thereof |
IT1311984B1 (it) * | 1999-03-26 | 2002-03-22 | Bioindustria Lab Italiano Medi | Procedimento per la preparzione di gabapentin. |
US6383471B1 (en) * | 1999-04-06 | 2002-05-07 | Lipocine, Inc. | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents |
US7056951B2 (en) * | 2000-09-26 | 2006-06-06 | Mutual Pharmaceutical Co., Inc. | Stable solid dosage forms of amino acids and processes for producing same |
US6979462B1 (en) * | 2000-10-03 | 2005-12-27 | Mutual Pharmaceutical Co., Inc. | Stabilization of solid drug formulations |
ES2380287T3 (es) * | 2001-06-11 | 2012-05-10 | Xenoport, Inc. | Profármacos de análogos de GABA, composiciones y sus usos |
-
1999
- 1999-05-10 AU AU40735/99A patent/AU768277B2/en not_active Ceased
- 1999-05-10 KR KR1020007012759A patent/KR100602047B1/ko not_active IP Right Cessation
- 1999-05-10 WO PCT/US1999/010190 patent/WO1999059573A1/en active IP Right Grant
- 1999-05-10 CN CNB998061557A patent/CN1303991C/zh not_active Expired - Fee Related
- 1999-05-10 DK DK99924166T patent/DK1077692T3/da active
- 1999-05-10 DE DE69918977T patent/DE69918977T2/de not_active Expired - Lifetime
- 1999-05-10 SI SI9930624T patent/SI1077692T1/xx unknown
- 1999-05-10 NZ NZ508015A patent/NZ508015A/en not_active IP Right Cessation
- 1999-05-10 PT PT99924166T patent/PT1077692E/pt unknown
- 1999-05-10 EP EP99924166A patent/EP1077692B1/en not_active Expired - Lifetime
- 1999-05-10 US US09/674,815 patent/US7309719B1/en not_active Expired - Fee Related
- 1999-05-10 CA CA002327285A patent/CA2327285C/en not_active Expired - Lifetime
- 1999-05-10 ID IDW20002352A patent/ID27724A/id unknown
- 1999-05-10 HU HU0102022A patent/HU228771B1/hu not_active IP Right Cessation
- 1999-05-10 PL PL344218A patent/PL204921B1/pl unknown
- 1999-05-10 ES ES99924166T patent/ES2221385T3/es not_active Expired - Lifetime
- 1999-05-10 BR BRPI9910508-0A patent/BR9910508B1/pt not_active IP Right Cessation
- 1999-05-10 IL IL13929899A patent/IL139298A0/xx unknown
- 1999-05-10 AT AT99924166T patent/ATE271864T1/de active
- 1999-05-12 TW TW088107704A patent/TWI243054B/zh not_active IP Right Cessation
- 1999-05-12 CR CR6026A patent/CR6026A/es unknown
- 1999-05-13 EG EG1999050554A patent/EG26803A/en active
- 1999-05-13 MY MYPI99001901A patent/MY157878A/en unknown
- 1999-05-13 PA PA19998472801A patent/PA8472801A1/es unknown
- 1999-05-14 HN HN1999000072A patent/HN1999000072A/es unknown
- 1999-05-14 JP JP13377399A patent/JP4612923B2/ja not_active Expired - Lifetime
- 1999-05-14 SV SV1999000064A patent/SV1999000064A/es active IP Right Grant
- 1999-05-14 UY UY25512A patent/UY25512A1/es not_active IP Right Cessation
- 1999-05-14 GT GT199900069A patent/GT199900069A/es unknown
- 1999-05-14 CO CO99030149A patent/CO5021224A1/es unknown
- 1999-05-14 AR ARP990102313A patent/AR020323A1/es active IP Right Grant
- 1999-05-14 PE PE1999000407A patent/PE20000556A1/es not_active Application Discontinuation
-
2000
- 2000-10-16 IS IS5666A patent/IS2233B/is unknown
- 2000-10-26 IL IL139298A patent/IL139298A/en not_active IP Right Cessation
- 2000-11-09 ZA ZA200006484A patent/ZA200006484B/en unknown
- 2000-11-14 NO NO20005768A patent/NO328959B1/no not_active IP Right Cessation
- 2000-11-15 CU CU20000256A patent/CU23253B7/es unknown
-
2001
- 2001-10-18 HK HK01107298A patent/HK1036586A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR020323A1 (es) | Preparaciones farmaceuticas estabilizadas que contienen derivados de acido 4-amino-3-substituido butanoico y proceso para prepararlos | |
MX2009004424A (es) | Peptidos inhibidores de la exocitosis neuronal. | |
ATE510852T1 (de) | Dermopharmazeutisch und kosmetisch wirksame oligopeptide | |
BR9914451A (pt) | Composto de oxazol, processo para sua preparação, composição farmacêutica compreendendo dito composto, uso da composição e métodos de tratamento | |
DE122009000040I1 (de) | Naphthalin-Derivate, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Zusammensetzungen. | |
NO173446C (no) | Analogifremgangsmaate til fremstilling av nye, terapeutisk aktive, substituerte alkandifosfonsyrer | |
FI80877B (fi) | Foerfarande foer framstaellning av terapeutiskt anvaendbara spiro/4,(3+n)/-2-azaalkan-3-karboxylsyraderivat och vid framstaellning av dessa anvaendbara foerening. | |
MX9102241A (es) | Analogos de gaba y de acido l-glutamico para tratamiento contra ataques. | |
AR033356A1 (es) | Compuesto que contiene una cadena lateral heterociclica, composicion farmaceutica que lo comprende y uso de dicho compuesto para la fabricacion de un medicamento | |
KR940008681A (ko) | 디클로페낙 염용 비경구 용액 | |
AR020016A2 (es) | Compuestos derivados de la eritromicina, composiciones que los contienen, uso de los mismos para preparar un medicamento | |
PT92378A (pt) | Processo para a preparacao de derivados de cromano, activos sobre o sistema nervoso central | |
RU2019118696A (ru) | Фармацевтические композиции, содержащие инсулин | |
ES2600179T3 (es) | Derivados de pantotenato para el tratamiento de trastornos neurológicos | |
BR0311363A (pt) | Formulação farmacêutica de liberação imediata, uso da mesma, e, método para tratar um distúrbio cardiovascular em um paciente | |
AR035451A1 (es) | Derivados de beta-carbolina, su uso para la fabricacion de un medicamento para el tratamiento de la depresion, ansiedad y desordenes bipolares, una composicion farmaceutica y una combinacion. | |
ES8608502A1 (es) | Procedimiento para la obtencion de benzofuranonas | |
ES2107688T3 (es) | Compuestos triciclicos con actividad farmaceutica. | |
ES543804A0 (es) | Procedimiento de preparacion de nuevos derivados a-etilben- zol con un grupo dialquilaminoalcoxi sustituido y de sus sa-les de adicion acidas y amonicas cuaternarias | |
ZA944727B (en) | Phosphonic acid compounds processes for preparing them and pharmaceutical compositions containing them | |
KR950700233A (ko) | 아미노산 유도체 및 항활성산소제(Amino acid derivatives and anti-active oxygen agents) | |
ES477167A1 (es) | Un procedimiento para la preparacion de sales del acido (-)-lis-1,2,epoxipropilfosforico. | |
BR9907166A (pt) | Composição farmacêutica e processo para estabilizar um composto possuindo um grupo éster opcional e um grupo à base de amidina | |
RU2012145458A (ru) | Соединения, используемые для лечения заболеваний, ассоциированных с экспрессией токсических транскриптов | |
GB1023204A (en) | New amino acids and process for their manufacture |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration |